PT - JOURNAL ARTICLE AU - David Gachoud AU - Trestan Pillonel AU - Tsilimidos Gerasimos AU - Dunia Battola AU - Dominique Dumas AU - Onya Opota AU - Stefano Fontana AU - Peter Vollenweider AU - Oriol Manuel AU - Gilbert Greub AU - Claire Bertelli AU - Nathalie Rufer TI - Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents AID - 10.1101/2022.04.24.22274200 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.24.22274200 4099 - http://medrxiv.org/content/early/2022/04/26/2022.04.24.22274200.short 4100 - http://medrxiv.org/content/early/2022/04/26/2022.04.24.22274200.full AB - Background Administration of plasma therapy may contribute to viral control and survival of COVID-19 patients receiving B-cell depleting agents that hinder the endogenous humoral response. However, little is known on the impact of anti-CD20 pre-exposition and the use of different sources of plasma (convalescent versus vaccinated) on the kinetics of SARS-CoV-2-specific antibodies and viral evolution after plasma therapy.Methods Eligible COVID-19 patients (n = 36), half of them after anti-CD20 targeted therapy, were treated with therapeutic plasma from convalescent (n = 17) or mRNA-vaccinated (n = 19) donors. Each plasma-transfused patient was thoroughly monitored over time by anti-S IgG quantification and whole-genome SARS-CoV-2 sequencing.Results The majority of anti-CD20 pre-exposed patients (15/18) showed progressive declines of anti-S protein IgG titers following plasma therapy, indicating that they mostly relied on the passive transfer of anti-SARS-CoV-2 antibodies. Such antibody kinetics correlated with prolonged infection before virus clearance, contrasting with the endogenous humoral response predominantly present in patients who had not received B-cell depleting agents (15/18). No relevant differences were observed between patients treated with plasma from convalescent and/or vaccinated donors. Finally, 4/30 genotyped patients showed increased intra-host viral evolution and 3/30 included 1 to 4 spike mutations, potentially associated to immune escape.Conclusions Convalescent and/or vaccinated plasma therapy may provide anti-SARS-CoV-2 antibodies and clinical benefit to B-cell depleted COVID-19 patients. Only a limited number of patients acquired viral mutations prior to clinical recovery, yet our study further emphasizes the need for long-term surveillance for intra-host variant evolution, to guide best therapeutic strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Lausanne University Hospital and University of Lausanne (Lausanne, Switzerland), and Interregional Blood Transfusion SRC (Bern, Switzerland).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cantonal ethics committee for clinical research of the canton Vaud (CER-VD, Lausanne, Switzerland) gave ethical approval for this work. Each patient or legally authorised representative provided informed consent prior to plasma transfusion and for the retrospective data collection. All patients described in this case series were treated with plasma therapy between November, 2020 and July, 2021 under an experimental therapy protocol available as compassionate use only, according to the Swiss Federal Law on Therapeutic Products (LPTh).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors